Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Anika Therapeutics (ANIK) Shares Outstanding (Weighted Average) (2016 - 2026)

Anika Therapeutics has reported Shares Outstanding (Weighted Average) over the past 17 years, most recently at $13.5 million for Q1 2026.

  • Quarterly Shares Outstanding (Weighted Average) fell 5.36% to $13.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $13.5 million through Mar 2026, down 5.36% year-over-year, with the annual reading at $14.3 million for FY2025, 2.59% down from the prior year.
  • Shares Outstanding (Weighted Average) was $13.5 million for Q1 2026 at Anika Therapeutics, down from $14.3 million in the prior quarter.
  • Over five years, Shares Outstanding (Weighted Average) peaked at $14.8 million in Q2 2024 and troughed at $13.5 million in Q1 2026.
  • The 5-year median for Shares Outstanding (Weighted Average) is $14.6 million (2022), against an average of $14.5 million.
  • Year-over-year, Shares Outstanding (Weighted Average) rose 1.29% in 2023 and then fell 5.36% in 2026.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $14.6 million in 2022, then grew by 0.65% to $14.7 million in 2023, then grew by 0.44% to $14.7 million in 2024, then fell by 2.59% to $14.3 million in 2025, then fell by 5.63% to $13.5 million in 2026.
  • Per Business Quant, the three most recent readings for ANIK's Shares Outstanding (Weighted Average) are $13.5 million (Q1 2026), $14.3 million (Q4 2025), and $14.4 million (Q3 2025).